SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Histogen Inc. (CIK 0001383701) — Jan 4, 2022

Histogen Inc. (CIK 0001383701)
Date: Jan. 4, 2022 · CIK: 0001383701 · Accession: 0001193125-22-001666

AI Filing Summary & Sentiment

File numbers found in text: 333-261839

Date
January 4, 2022
Author
Not clearly detected
Form
CORRESP
Company
Histogen Inc. (CIK 0001383701)

Letter

January 4, 2022

Via EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, DC 20549-4561

Attn: Michael Davis

Laura Crotty

Re: Histogen, Inc.

Registration Statement on Form S-3

File No. 333-261839

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, Histogen, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effectiveness of the above-referenced Registration Statement to 5:00 p.m., Eastern Standard Time, on Wednesday, January 5, 2022, or as soon thereafter as practicable.

Please contact Larry Nishnick of DLA Piper LLP (US) with any questions or comments at (858) 677-1414. Thank you for your assistance with this filing.

Very truly yours,
Histogen, Inc.

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

 January 4, 2022

Via EDGAR

 Securities and Exchange Commission

Division of Corporation Finance

 100 F Street, NE

Washington, DC 20549-4561

Attn:
 Michael Davis

 Laura Crotty

Re:
 Histogen, Inc.

Registration Statement on Form S-3

File No. 333-261839

Ladies and Gentlemen:

 Pursuant
to Rule 461 of the Securities Act of 1933, as amended, Histogen, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effectiveness of the
above-referenced Registration Statement to 5:00 p.m., Eastern Standard Time, on Wednesday, January 5, 2022, or as soon thereafter as practicable.

Please contact Larry Nishnick of DLA Piper LLP (US) with any questions or comments at (858) 677-1414.
Thank you for your assistance with this filing.

Very truly yours,

Histogen, Inc.

By:

 /s/ Susan A. Knudson

Name:

Susan A. Knudson

Title:

Chief Financial Officer

CC:
 Steven J. Mento, Ph.D., Histogen, Inc.

Larry Nishnick, DLA Piper LLP (US)